A 2 Week Blinded Study For Pain Due To Arthritis Of The Knee

Pfizer

Status and phase: Terminated; Phase 2

Conditions: Osteoarthritis

Treatments: Drug: Oxycodone; Drug: Placebo; Drug: PF-000592379

Study type: Interventional

Funder types: Industry

Identifiers

NCT00483977

A7771010

Details and patient eligibility

About

The primary aim is to assess if PF-00592379 is able to reduce pain in patients with osteoarthritis of the knee.

Enrollment: 113 patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Male or female of any race
• Between the ages of 18 and 75 years
• Knee Pain due to osteoarthritis

Exclusion criteria

• Pregnant
• Participation in a clinical trial for an investigational drug and/or agent within 30 days prior to baseline
• History of malignancy, convulsions, chronic infections, arthroscopy of the worst knee within the past year

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

113 participants in 3 patient groups, including a placebo group

Oxycodone

Active Comparator group

Treatment:

Drug: Oxycodone

Placebo

Placebo Comparator group

Treatment:

Drug: Placebo

PF-00592379

Experimental group

Treatment:

Drug: PF-000592379